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Two double-blind, randomized studies were conducted to assess the tolerability, pharmacokinetics
and pharmacodynamics of oral TA-8995, a new cholesteryl ester transfer protein (CETP) inhibitor,
in healthy subjects.
METHODS
Study 1: Subjects received single doses of TA-8995 or placebo (fasted). Doses were 5, 10, 25, 50
(fed/fasted), 100 and 150 mg (Caucasian males, 18–55 years), 25 mg (Caucasian males, > 65 years
and Caucasian females, 18–55 years), 25, 50, 100 and 150 mg (Japanese males, 18–55 years). Study
2: Caucasian males (18–55 years) received 1, 2.5, 10 or 25 mg once daily TA-8995 or placebo for
21–28 days. Blood and urine for pharmacokinetics and/or pharmacodynamics were collected.
Tolerability was assessed by adverse events, vital signs, electrocardiograms and laboratory safety
tests.
RESULTS
Peak TA-8995 concentrations occurred approximately 4 h post-dose. Mean half-lives ranged from
81 to 166 h, without an obvious dose relationship. Exposure increased less than proportionally to
dose. TA-8995 was not excreted in urine. Following 2.5 to 25 mg once daily dosing, TA-8995
demonstrated nearly complete inhibition of CETP activity (92–99%), increased high density
lipoprotein-cholesterol (HDL-C) by 96 to 140% and decreased low density liporotein-cholesterol
(LDL-C) by 40% to 53%. There were dose-related increases in apolipoproteins A-1 and E, HDL2-C
and HDL3-C, and decreases in apolipoprotein B and lipoprotein A. There was no evidence of
significant effects of age, gender, ethnicity or food on pharmacokinetics or pharmacodynamics. All
doses were well tolerated.
CONCLUSIONS
TA-8995 is a potent CETP inhibitor and warrants further investigation.
WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Cholesteryl ester transfer protein (CETP) inhibitors have
previously been shown to increase high density
lipoprotein (HDL)-cholesterol and reduce low density
lipoprotein (LDL)-cholesterol in humans with varying
potency.
• Development has been limited by adverse events
(thought to be linked to off-target pharmacology) and
lack of potency.
WHAT THIS STUDY ADDS
• Single and multiple doses of TA-8995, a novel selective
CETP inhibitor, demonstrate near complete CETP
inhibition and are well tolerated in healthy subjects.
• There was no evidence of any off-target effects that are
implicated in the toxicity of other compounds, such as
changes in blood pressure, serum electrolytes or
aldosterone.
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Introduction
Prospective epidemiological studies have shown a strong
association between low density lipoprotein-cholesterol
(LDL-C) concentrations and cardiovascular disease risk [1].
The subsequent application of statin therapy to decrease
these atherogenic LDL-C concentrations has resulted in a
marked reduction of cardiovascular-related morbidity and
mortality. Every 1 mmol l−1 decrease in LDL-C results in an
estimated 22% reduction of cardiovascular events and a
10% reduction of all-cause mortality [2]. Notwithstanding
these impressive benefits, a large residual disease burden
persists that has a large impact on both individual patients
as well as on global healthcare costs [3]. Novel therapeu-
tics are required to reduce further this residual cardiovas-
cular risk in patients. Therapies that modify high density
lipoprotein-cholesterol (HDL-C) concentrations would be a
logical next step as a large body of evidence has shown an
inverse association between HDL-C concentrations and
cardiovascular disease risk ( [1].
One way to elevate HDL-C concentrations is to inhibit
cholesteryl ester transfer protein (CETP). CETP is a plasma
protein secreted primarily by liver and adipose tissue. CETP
mediates the transfer of cholesteryl esters from HDL to
apolipoprotein B-containing particles (mainly LDL and
VLDL) in exchange for triglycerides, thereby decreasing
the cholesterol content in HDL in favour of that in (V)LDL.
Hence, CETP inhibition has been hypothesized to retain
cholesteryl esters in HDL-C and decrease the cholesterol
content of the atherogenic apolipoprotein B fraction.
Large Mendelian randomization studies and meta-
analyses have shown that CETP variants that result in lower
CETP activity are associated with a decreased risk of car-
diovascular disease [4–7]. In addition, pharmacological
CETP inhibition in rabbits resulted in reduced atheroscle-
rotic plaque formation [8]. Taken together there is ample
evidence in support of CETP inhibition in humans as a
therapeutic target. The rationale for CETP inhibition and
pre-clinical data was recently reviewed by others [9, 10].
The aims of the studies discussed in this paper were to
assess the tolerability, pharmacokinetics and pharma-
codynamics of a new potent CETP inhibitor, TA-8995 (a
derivative of 4-{2-[benzyl-(1,2,3,4-tetrahydro-quinolin-4-




In both studies, subjects had to be healthy, weigh at least
50 kg (males) or 45 kg (females), and have a body mass
index of 18 to 33 kg m−2 with a waist measurement of
≤91 cm. Female subjects had to be of non-childbearing
potential. All subjects had to provide written informed
consent and be prepared to comply with study require-
ments. Key exclusion criteria included HDL-C ≥
2.59 mmol l−1 at screening or baseline and clinically rel-
evant findings from medical history, physical examination,
laboratory tests, 12-lead ECG or Holter assessment. A
family history of long QT syndrome, hypokalaemia or
torsades de pointes was also excluded. Use of any non-
study medication was restricted as was the intake of
alcohol and nicotine-containing products.
Study design
Two randomized, double-blind, placebo-controlled,
parallel-group studies were conducted in healthy subjects
to investigate the tolerability, pharmacokinetics and phar-
macodynamics of TA-8995 (a tetrahydroquinoline). Both
studies were conducted in accordance with the Interna-
tional Conference on Harmonization guideline for Good
Clinical Practice and the principles of the Declaration of
Helsinki, and were reviewed and approved by the local
Ethics Committees (see Supporting Information) and Com-
petent Authorities.
The first study (study 1) was a single dose study in 12
groups of subjects. Six groups of Caucasian male subjects
aged 18 to 55 years received single oral doses of 5, 10, 25,
50, 100 and 150 mg TA-8995 or placebo under fasting con-
ditions. The subjects who received 50 mg TA-8995/
placebo also received the same dose following a high fat
meal 4 weeks after the fasting dose. A further group of
Caucasian males aged at least 65 years and a group of
Caucasian females aged 18 to 55 years received single
doses of 25 mg TA-8995 or placebo (fasted). Four groups of
Japanese male subjects aged 18 to 55 years received single
oral doses of 25, 50, 100 and 150 mg TA-8995 or placebo
(fasted). Subjects in each group/dose level were allocated
to study treatment in a ratio of six TA-8995 to two placebo.
Blood samples for pharmacokinetic and pharmacody-
namic assessments were collected from prior to each dose
and at intervals up to 336 h post-dose. Urine was collected
for pharmacokinetics from pre-dose and at intervals up to
72 h post-dose from selected dose groups. The primary
pharmacodynamic endpoints included CETP activity, CETP
concentration, HDL-C, LDL-C, total cholesterol and
triglycerides. Secondary pharmacodynamic endpoints
included apolipoproteins A1, B and E, HDL2-C and HDL3-C.
Pharmacodynamic samples were not collected during the
fed period, with the exception of HDL-C, LDL-C, total cho-
lesterol and triglycerides which were collected as part of
the biochemistry assessments.
The second study (study 2) was a repeated dose study
in five groups of Caucasian male subjects aged 18 to
55 years. Each subject received a single oral dose of
TA-8995/placebo on day 1, followed by once daily doses
on days 8 to 35 (5 mg TA-8995/placebo – group 1) or days
8 to 28 (1, 2.5, 10 and 25 mg TA-8995/placebo – groups 2 to
5). All doses were administered at the study centre after a
standard breakfast. Subjects in each dose group were allo-
cated to study treatment in a ratio of 10 TA-8995 to two
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Br J Clin Pharmacol / 78:3 / 499
placebo. Blood samples for pharmacokinetic and
pharmacodynamic (CETP activity, CETP concentration,
HDL-C, LDL-C, total cholesterol, triglycerides) assessments
were collected from prior to each dose and at intervals
throughout the study until 336 h after the last dose.
Secondary pharmacodynamic endpoints (including
apolipoproteins A1, A2, B and E, lipoprotein a [Lp(a)],
HDL2-C, HDL3-C, phospholipids, HDL-free cholesterol
[HDL-FC], HDL-cholesteryl ester [HDL-CE], HDL-
phospholipids [HDL-PL], HDL-triglycerides [HDL-TG] and
LDL particle size) were measured at intervals until the last
day of dosing. Urine was collected for pharmacokinetics
from pre-dose and at intervals up to 72 h after the first and
last dose.
Tolerability assessments including adverse events,
blood pressure and pulse rate, ECGs, laboratory safety
tests (including aldosterone) and physical examinations
were conducted throughout both studies.
Details of the analytical methods for the pharma-
cokinetic and pharmacodynamic endpoints are presented
in the Supporting Information.
Statistical analyses
The sample sizes for each study were chosen based on
practical considerations rather than statistical power given
that these studies represented the first studies in humans.
The numbers of subjects in each group were considered to
be adequate to assess the main objectives of each study.
Subjects were allocated to TA-8995 or placebo in each
group by means of a computer-generated randomization
code. Pharmacokinetic parameters were determined by
non-compartmental methods using WinNonlin software
version 4.1 (Pharsight Corporation, USA). All data were
listed and summarized by treatment group using descrip-
tive statistics. The effects of food, ethnicity, age and
gender on the single dose pharmacokinetics of TA-8995
were investigated in study 1 using log-transformed Cmax
and AUC parameters and an analysis of variance (ANOVA)
model. The back-transformed point estimates and 90%
confidence intervals for the various comparisons (ratios)
are presented. In study 2, a post hoc analysis was con-
ducted to compare the maximum percent changes from
baseline at each TA-8995 dose level with pooled placebo
using an ANOVA model. All statistical analyses were con-
ducted using SAS version 6.12 or higher (SAS Institute Inc.
USA).
Results
Study 1 was conducted between March 2008 and June
2009 and study 2 was conducted between August 2009
and June 2010. A total of 96 subjects were enrolled into
study 1 and 95 subjects completed the study: one Cauca-
sian subject (50 mg TA-8995) withdrew due to personal
reasons in period 1 (food effect group) and was not
replaced. A total of 61 subjects were enrolled into study 2
and 59 subjects completed the study: one subject (10 mg
TA-8995) was withdrawn on day 7, due to a protocol vio-
lation and one subject (placebo) withdrew on day 13 for
personal reasons. No subjects were withdrawn from either
study due to adverse events. Flow charts detailing subject
participation are included in Supporting Information
Figures S1 and S2.
Pharmacokinetics
Following single oral doses from 5 to 150 mg in study 1,
TA-8995 was absorbed and peak concentrations were
typically achieved 3 to 4 h post-dose (Table 1, Figure 1).
Plasma concentrations increased less than proportionally
to dose with eight-fold, 14-fold and 15-fold increases in
AUC(0,336 h), AUC(0,24 h) and Cmax, respectively being
observed for a 30-fold increase in dose. Within each dose
group, variability was moderate with coefficients of varia-
tion (CV) for Cmax and AUC parameters being 8 to 39% with
the exception of 100 mg TA-8995, where variability was
greater over the first 24 h post-dose. Mean terminal half-
life of TA-8995 varied across the dose range from 81 to
166 h, without an obvious relationship to dose. No clini-
cally relevant effects of food, age, gender or ethnicity on
TA-8995 pharmacokinetics were observed (Table 2).
In study 2, plasma concentrations appeared to increase
approximately proportionally to dose following single
Table 1















Cmax (ng ml−1) 138 (33%) 251 (23%) 467 (30%) 855 (21%) 1553 (78%) 2090 (26%)
tmax (h) 3 (2, 3) 3 (2, 5) 3.5 (2, 6) 4 (3, 5) 4 (1, 10) 4 (3, 5)
AUC(0,24 h) (ng ml−1 h) 1816 (34%) 3580 (21%) 5952 (26%) 11117 (28%) 21166 (59%) 26403 (20%)
AUC(0,336 h) (ng ml−1 h) 10351 (30%) 19250 (32%) 32985 (25%) 44353 (10%) 73359 (36%) 78200 (23%)
AUC(0,∞) (ng ml−1 h) 12078 (32%) 22554 (39%) 42385 (24%) 57189 (8%) 77323 (36%) 84652 (29%)
t1/2 (h) 125 (22%) 124 (20%) 162 (19%) 166 (21%) 80.9 (17%) 95.9 (23%)
*Values are geometric mean (CV%) for Cmax and AUC parameters, median (minimum, maximum) for tmax and arithmetic mean (CV%) for t1/2. CV = coefficient of variation.
J. Ford et al.
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doses from 1 to 25 mg, although non-proportionality was
observed at steady-state: seven-fold, nine-fold and 12-fold
increases in Cmin,ss, AUC(0,τ,ss) and Cmax,ss, respectively for a
25-fold increase in dose (Table 3). tmax was independent of
dose with median values of 4 to 6 h post-dose. Variability
was moderate following single and repeated dosing with
CVs for Cmax, Cmin and AUC parameters being ≤33%. Visual
inspection of trough concentrations suggests that
TA-8995 approached steady-state within 1 to 2 weeks of
daily dosing (Figure 2). The mean terminal half-life of
TA-8995 following the last dose was 121 to 151 h and was
independent of dose. A similar half-life was observed after
single and repeated doses of 5 to 25 mg of TA-8995,
respectively. TA-8995 accumulated with once daily dosing
in a dose-dependent manner, with an approximately six-
fold increase at 1 mg through to a two-fold increase at
25 mg.
TA-8995 was not detected in the urine in either study.
Pharmacodynamics
Baseline pharmacodynamic parameters were well bal-
anced across treatment groups in study 1 (data not shown)
and study 2 (Table 4 and Supporting Information Table S1).
TA-8995 strongly inhibited CETP activity in a dose-
dependent manner following both single and repeated
dosing (Figure 3A). Near complete CETP inhibition was
observed following a single dose of 25 mg TA-8995 (∼94%)
and following repeated doses of 2.5, 5, 10 to 25 mg once
daily TA-8995 (∼92 to 99%) (Table 5). This level of inhibition
was maintained throughout the repeated dosing period
and the maximum effect of each dose was achieved within
1 week of once daily dosing. The duration of inhibition
after the last dose was dose-dependent, with activity
approaching baseline levels by 2 weeks following the
lowest dose (1 mg), but still being approximately 50%
below baseline at 2 weeks following 10 and 25 mg dosing.
Although CETP activity decreased with TA-8995 dosing,
the concentration of CETP increased in a dose-dependent
manner following both single and repeated dosing
(Figure 3B). CETP concentration increased from baseline
by 250% to 280% after 3 weeks of dosing with 10 mg and
25 mg once daily TA-8995. CETP concentrations declined
in parallel for each dose, such that following the cessation
of TA-8995 dosing, CETP concentrations were approaching
baseline values within 2 weeks following 1 mg and 5 mg
TA-8995, whereas CETP concentrations were still approxi-
mately 140% higher than baseline at 2 weeks following
10 mg and 25 mg TA-8995. The maximum percent
changes in CETP activity and CETP concentrations
were statistically significantly different from placebo
(P < 0.0001) at all TA-8995 dose levels (1 to 25 mg). The
differences in least squares means and 95% confidence
intervals are presented in Supporting Information Table
S2.
HDL-C concentrations increased in a dose-dependent
manner following both single and repeated dosing
(Figure 3C). Once daily TA-8995 at doses of 2.5 to 25 mg
led to marked increases from baseline HDL-C of approxi-
mately 96% up to 140%. LDL-C concentrations decreased
in a dose-dependent manner with maximum changes
from baseline of approximately −40% to −53% following
2.5 to 25 mg once daily TA-8995 (Figure 3D, Table 5). The
maximum percent changes from baseline were statistically
significantly different from placebo (P < 0.0001) following
once daily TA-8995 doses of 5 to 25 mg for HDL-C and
following 10 and 25 mg for LDL-C. HDL-C and LDL-C con-
centrations started to return towards baseline following
cessation of TA-8995 dosing consistent with the loss of
CETP inhibition.
There were trends indicating dose-related increases
in apolipoproteins A1 and E, HDL2-C and HDL3-C and
decreases in apolipoprotein B and Lp(a) concentrations
(Supporting Information Figure S3). Variability was high for
all of those variables. Nevertheless the data suggest that
maximum effects may have been achieved with doses of 5
to 10 mg once daily TA-8995. There was no dose-related
trend in apolipoprotein A2 or phospholipids (Supporting
Information Figure S3), but there were dose-related
increases in HDL-FC, HDL-CE and HDL-PL and decreases in
HDL-TG across the dose range 1 to 10 mg with no further
changes noted at 25 mg TA-8995 (data not shown). There
were no noteworthy changes in LDL particle size (data not
shown).
No consistent dose-related changes were observed for
total cholesterol and triglycerides following TA-8995
dosing (Figure 3E, F).
Similar trends were observed for the pharma-
codynamic variables in study 1 following single doses of































Mean (SD) TA-8995 plasma concentration vs. time profiles following
single dose administration to Caucasian males under fasting conditions
(study 1). , 5 mg; , 10 mg; , 25 mg; , 50 mg; , 100 mg; ,
150 mg
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in CETP activity and LDL-C concentration and increases in
CETP and HDL-C concentrations were observed (data not
shown). No consistent effects on total cholesterol or
triglycerides were observed in study 1. In addition, there
was no evidence of any clinically relevant effect of
food, age, gender or ethnicity on the pharmacodynamic
variables.
Tolerability
Single doses of TA-8995 up to 150 mg and repeated doses
up 25 mg once daily were well tolerated in all subjects.
There were no serious adverse events and no subjects
withdrew because of adverse events. The only adverse
events reported by more than two subjects in either study
were headache, epistaxis, pharyngolaryngeal pain,
rhinorrhoea, nasopharyngitis, upper abdominal pain and
myalgia. The incidence of those events was not dose-
related (see Supporting Information Tables S3 and S4).
There were no clinically significant effects on blood
pressure or heart rate, ECG variables, physical examination
or laboratory safety tests (other than those discussed
under pharmacodynamics). In particular, TA-8995 had no
effect on serum electrolyte or aldosterone concentrations.
Discussion
Despite the evidence supporting the potential of CETP
inhibition in reducing cardiovascular morbidity, clinical
development of CETP inhibitors has not been straightfor-
ward. The first compound to progress to phase 3 clinical
trials was torcetrapib. Torcetrapib was shown to increase
HDL-C by 72% and decrease LDL-C by 25%, but it was
subsequently withdrawn from development owing to
safety concerns including an unexpected increase in car-
diovascular events and death when in combination with
Table 2
Statistical comparison to assess the effect of food, age, gender and ethnicity on the pharmacokinetics of single oral doses of TA-8995 (study 1)
Comparison (TA-8995 dose) Parameter Least squares means ratio 90% confidence interval
Fed vs. fasted (50 mg) Cmax 108.9 84.5,140.5
AUC(0,336 h) 115.8 106.7,125.7
AUC(0,∞) 98.4 88.4,109.5
Elderly vs. young (25 mg) Cmax 111.4 87.9,141.2
AUC(0,336 h) 88.1 69.0,112.3
AUC(0,∞) 92.5 70.4,121.6
Female vs. male (25 mg) Cmax 118.0 77.6,179.3
AUC(0,336 h) 101.5 71.3,144.6
AUC(0,∞) 93.8 67.9,130.0
Japanese vs. Caucasian (all doses) Cmax 137.8 101.5,187.1
AUC(0,336 h) 103.7 80.2,134.3
AUC(0,∞) 95.0 72.9,123.7
Table 3
Pharmacokinetic parameters for TA-8995 following single and repeated oral doses in Caucasian male healthy subjects (Study 2)
Parameter (unit)*












Cmax (ng ml−1) 27.0 (19%) 65.7 (13%) 116 (13%) 245 (14%) 750 (19%)
tmax (h) 6 (4, 12) 6 (4, 8) 6 (4, 8) 6 (4, 8) 6 (3, 8)
AUC(0,24 h) (ng ml−1 h) 434 (25%) 1055 (12%) 1796 (14%) 3471 (18%) 10437 (21%)
Steady-state†
Cmax,ss (ng ml−1) 121 (19%) 256 (20%) 436 (18%) 692 (23%) 1398 (18%)
tmax,ss (h) 4 (3, 12) 4 (2, 8) 4 (3, 8) 6 (4, 8) 4 (2, 6)
Cmin,ss (ng ml−1) 83.4 (19%) 172 (20%) 237 (20%) 396 (33%) 553 (26%)
AUC(0,τ,ss) (ng ml−1 h) 2462 (19%) 5013 (18%) 7606 (20%) 12707 (27%) 21493 (21%)
t1/2,ss (h) 138 (16%) 151 (15%) 148 (30%) 131 (19%) 121 (23%)
Rac 5.8 (1.3) 4.8 (0.9) 4.3 (1.1) 3.7 (0.8) 2.1 (0.3)
*Values are geometric mean (CV%) for Cmax, Cmin and AUC parameters, median (minimum, maximum) for tmax, arithmetic mean (CV%) for t1/2, and arithmetic mean (SD) for Rac.
†Assessed after the last dose: day 42 for 5 mg TA-8995 and day 35 for other doses. CV = coefficient of variation, Rac = accumulation ratio calculated as AUC(0,τ,ss)/AUC(0,24 h),
where τ is the dosing interval (24 h).
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atorvastatin, compared with atorvastatin alone [11].
Although the mechanism of those events is not fully
understood, there is increasing evidence that they might
have been due to off-target effects of torcetrapib such as
increased blood pressure, changes in electrolytes
(increases in sodium and bicarbonate and decreases in
potassium) and increases in aldosterone, consistent with
mineralocorticoid activity [11–15]. There is also some evi-
dence from animal studies that torcetrapib increases
expression of endothelin-1, which has been postulated to
have contributed to the apparent increase in vascular
deaths and possibly the (non-significant) increase in
cancer deaths in the ILLUMINATE trial [16, 17]. Subse-
quently another CETP inhibitor, dalcetrapib, entered phase
2B clinical trials. Dalcetrapib was shown to be a weak
inhibitor that increased HDL-C by 30–40% with minimal
effects on LDL-C concentrations but did not appear to
exhibit the off-target effects of torcetrapib [18–20]
Recently, dalcetrapib development has also been termi-
nated on the grounds of futility i.e. it did not reduce the
risk of recurrent cardiovascular events [18].
Two more CETP inhibitors, anacetrapib and
evacetrapib, are currently in phase 3 clinical trials. Data
from phase 2 studies suggest that both are potent CETP
inhibitors without mineralocorticoid activity. Anacetrapib
200 mg once daily has been shown to increase HDL-C by
97% and decrease LDL-C by 36% in healthy subjects [21]
and 100 mg once daily anacetrapib in combination with
statins has been shown to increase HDL-C by 149% and
decrease LDL-C by 45% in patients [22]. Evacetrapib
(500 mg once daily monotherapy in patients) has been
shown to increase HDL-C by 129% and decrease LDL-C by
36% [23]. No outcome data are available currently to
confirm whether this apparent improved potency over
torcetrapib and dalcetrapib translates into a reduction in
cardiovascular risk.
Data from these initial clinical trials of TA-8995 in
healthy subjects have shown that it is also a potent CETP
inhibitor with near maximal inhibition of CETP activity
being observed with once daily doses of 2.5 mg TA-8995
and above. Inhibition of CETP activity was associated with
increases in HDL-C of up to 140% and decreases in LDL-C
of up to 44% (53% observed with 25 mg) with once daily
doses of 10 mg TA-8995. Similar changes were observed
for 200 mg anacetrapib (which increased HDL-C by 97%
when given fasted and 123% when fed and decreased
LDL-C by 36% [fasted] to 56% [fed]) [21] and 500 mg
evacetrapib (which increased HDL-C by 129%, and
decreased LDL-C by 36%) [23]. The effects of TA-8995
were maintained throughout the dosing period and
then returned steadily towards baseline after cessation
of TA-8995 dosing. Despite the reduction in CETP
activity observed with TA-8995, CETP concentration
increased during the dosing period but declined during
the follow-up period. That apparent induction of
CETP mass has also been noted with other CETP inhibi-
tors [24].
There was no dose-related effect of TA-8995 on total
cholesterol concentration, presumably because of the
conflicting effects of TA-8995 on the various sub-
components including HDL-C, LDL-C and their related
lipoproteins. There was also no dose-related effect on
triglyceride concentrations. Similar effects have been
reported for anacetrapib [21] although evacetrapib has
been shown to reduce triglycerides at high doses
(500 mg). Whilst there is strong evidence that decreased
HDL-C and increased LDL-C are indicators of increased car-
diovascular risk, the relevance of changes in triglycerides is
still unclear [1].
TA-8995 also appeared to increase the HDL-C
apolipoproteins A1 and E as well as the HDL subfractions
HDL2-C and HDL3-C and phospholipids, and decrease the
LDL-C apolipoprotein B as well as Lp(a). Decreased
apolipoprotein A1 and elevated apolipoprotein B are rec-
ognized markers of cardiovascular disease [25–27].
In total, such changes in atherogenic lipoproteins,
accompanied by an increase of the HDL-2 fraction and
apolipoproteins A1 and E, support the hypothesis that
TA-8995 treatment would decrease cardiovascular disease
risk.
The potential of TA-8995 to lower Lp(a) is also of par-
ticular interest, as increased Lp(a) concentrations have
been found to be a causal factor for cardiovascular disease,
myocardial infarction and aortic stenosis and there is an
urgent need for drugs to treat high Lp(a) [28–32]. A longi-
tudinal cohort study demonstrated that lipid apheresis
combined with lipid-lowering medication in 120 patients
with coronary artery disease significantly decreased Lp(a)
concentrations (by approximately 75%) and also signifi-






























Mean (SD) TA-8995 plasma concentration vs. time profiles following
single and repeated (once daily) dose administration (study 2). , 1 mg;
, 2.5 mg; , 5 mg; , 10 mg; , 25 mg
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by 86% (>95% for myocardial infarction) [33]. Although no
randomized studies have yet shown that lowering Lp(a)
decreases cardiovascular risk, the data are encouraging
and, as a result, a reimbursement structure is now in place
in Germany to treat high risk patients with lipoprotein
apheresis.
A recent study of anacetrapib suggests that its
pharmacodynamic effects may persist for many weeks
after cessation of therapy [24]. In particular, increases in
HDL-C and decreases in LDL-C were still apparent 8 weeks
after the end of an 8 week dosing period. Those effects
appear to be related to the persistence of anacetrapib in
plasma, and the authors conclude that anacetrapib may
have a terminal half-life of 3 to 4 weeks. That is much
longer than the 60–80 h previously quoted in healthy sub-
jects [21]. Whilst a difference in the pharmacokinetics of
anacetrapib between healthy subjects and patients
cannot be excluded, it is also possible that the sampling
period in the phase 1 studies (up to 120 h after the last
dose) was too short to characterize adequately the true
terminal half-life. In the studies described here, TA-8995
concentrations were measured for 336 h after the final
dose, so the calculated half-life of 120–150 h after
repeated dosing probably represents the true terminal
phase. Likewise, the steady return to baseline of the
affected pharmacodynamic variables after cessation of
dosing, also suggests that long term residual activity of
TA-8995 is unlikely.
Pharmacokinetic data suggest that TA-8995 is well
absorbed after oral administration with peak plasma con-
centrations typically observed within 4 to 6 h post-dose.
Importantly there was no evidence of a clinically relevant
effect of food on either the pharmacokinetics or pharma-
codynamics of TA-8995. This was in contrast with the sig-
nificant food effect observed with anacetrapib where a
high fat meal increases AUC(0,∞) and Cmax by six- and
eight-fold, respectively, compared with fasting conditions
[34]. Non-proportional pharmacokinetics of TA-8995 were
observed with lower than expected increases in Cmax and
AUC relative to increasing dose. Despite its long half-life,
TA-8995 trough concentrations appeared to reach steady-
state within 1 to 2 weeks of repeated dosing. TA-8995 is
not renally cleared, as no drug could be detected in the
urine.
Overall the data from these two studies suggest that
TA-8995 is well tolerated at doses higher than those
needed for adequate CETP inhibition. Importantly there
was no evidence of any of the off-target effects that are
implicated in the toxicity of torcetrapib, such as changes in
blood pressure, serum electrolytes (including sodium,
potassium and bicarbonate) or aldosterone.
These studies confirm that TA-8995 is a potent inhibitor
of CETP activity in humans. This inhibition leads to signifi-
cant elevations in HDL-C and apolipoprotein A1 and
reductions in LDL-C and apolipoprotein B. Promising
trends in other markers of cardiovascular risk, such as
Lp(a), were also observed. In addition, although TA-8995
appears to have similar potency to other CETP inhibitors in
clinical development, it may offer benefits in terms of dose
size, lack of food effects and lack of prolonged residual
effects on cessation of dosing. Further studies are war-
ranted in patients with cardiovascular risk factors to deter-
mine whether these findings translate into clinical benefit.
A phase 2 multicentre, randomized, double-blind,
placebo-controlled study of TA-8995 in patients with mild
dyslipidaemia, alone and in combination with statin
therapy, is now in progress.
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Figure 3
Mean (SD) percentage change from baseline in CETP activity (A), CETP concentration (B), HDL-C (C), LDL-C (D), total cholesterol (E) and triglycerides (F)
following single and repeated (once daily) dosing of TA-8995 and placebo (study 2). Group 1 received TA-8995 (5 mg)/placebo on day 1 and on days 8–42.
Groups 2–5 received TA-8995 (1, 2.5, 10 or 25 mg)/placebo on day 1 and on days 8–35. , 1 mg; , 2.5 mg; , 5 mg; , 10 mg; , 25 mg; , placebo
(Group 1); , placebo (Group 2–5)
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